BioXcel Therapeutics, Inc. (BTAIQ) stock
BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
$0.03−0.00 (-13.49%)
Close on Oct 19, 2026Market cap $757.50KP/E –Yield –
BioXcel Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
BioXcel Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -9549.9%. For fiscal 2025 it was -10887.4%, against -2630.1% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -10887.4% | −8257.2 |
| FY2024 | Dec 31, 2024 | -2630.1% | +10344.7 |
| FY2023 | Dec 31, 2023 | -12974.9% | +31227.0 |
| FY2022 | Dec 31, 2022 | -44201.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -8084.1% | +7905.1 |
| Q1 FY2026 | Mar 31, 2026 | -6160.7% | −1842.8 |
| Q4 FY2025 | Dec 31, 2025 | -4900.4% | −1933.5 |
| Q3 FY2025 | Sep 30, 2025 | -31541.8% | −25163.3 |
| Q2 FY2025 | Jun 30, 2025 | -15989.2% | −15237.4 |
| Q1 FY2025 | Mar 31, 2025 | -4317.9% | +285.4 |
| Q4 FY2024 | Dec 31, 2024 | -2966.9% | +2952.2 |
| Q3 FY2024 | Sep 30, 2024 | -6378.5% | +8426.8 |
| Q2 FY2024 | Jun 30, 2024 | -751.7% | +10958.3 |
| Q1 FY2024 | Mar 31, 2024 | -4603.3% | +21025.9 |
| Q4 FY2023 | Dec 31, 2023 | -5919.1% | +17109.4 |
| Q3 FY2023 | Sep 30, 2023 | -14805.3% | +15709.3 |
| Q2 FY2023 | Jun 30, 2023 | -11710.1% | – |
| Q1 FY2023 | Mar 31, 2023 | -25629.1% | – |
| Q4 FY2022 | Dec 31, 2022 | -23028.6% | – |
| Q3 FY2022 | Sep 30, 2022 | -30514.6% | – |
See a number that looks wrong?